Gen Pharma News Today

Especially endless whining about the strong dollar and how it is killing the translation. That is all i heard today. It was the proximate cause of the downturn in the market. Nasdaq plunging 8. 9 now look i get that the dollar is strong against a number of currencies and that hurt. Believe me if this were not an hermes tie and if this booze were not actually worth drinking i would be pouring the wine of all of these great countries all over this dirty floor, which is usually meant for sipping ch...

NervGen Pharma Corp. a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the company has granted 950,000...

Vancouver, British Columbia--(Newsfile Corp. - June 6, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) a clinical-stage biotech company dedicated to developing innovative solutions for the treatment

UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that management will participate in a virtual fireside chat at the TD Cowen 5th...

UroGen Pharma (NASDAQ:URGN – Free Report) had its price target cut by Oppenheimer from $34.00 to $32.00 in a research report sent to investors on Tuesday, Benzinga reports. They currently have an outperform rating on the stock. Separately, HC Wainwright reaffirmed a buy rating and set a $54.00 target price on shares of UroGen Pharma […]

NervGen Pharma Corp. , a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Daniel Mikol, MD, Ph.D., Chief...

NervGen Pharma Corp. , a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, reported its financial and operational results for the...

NervGen Pharma Corp. , a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that it has engaged Russo Partners LLC , a...

Equities Research Analysts’ updated eps estimates for Thursday, April 4th: Arbutus Biopharma (NASDAQ:ABUS) had its market outperform rating reaffirmed by analysts at JMP Securities. JMP Securities currently has a $4.00 price target on the stock. Arcellx (NASDAQ:ACLX) had its outperform rating reaffirmed by analysts at Scotiabank. The firm currently has a $82.00 target price on […]

Shares of Landos Biopharma, Inc. (NASDAQ:LABP) rose sharply during Monday’s session following acquisition news. AbbVie Inc. (NYSE:ABBV) an...